
Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC While Radium-223 Sequencing Requires Further ...
Although findings from the phase 3 PEACE-3 trial (NCT02194842) demonstrated a progression-free survival (PFS) benefit with radium-223 (Xofigo) plus enzalutamide (Xtandi) in patients with bone-predominant metastatic castration-resistant prostate cancer ( …